GLPwatch
Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety.
PLoS Med · 2026
Last updated 2026-05-28GLP-1 drugs like semaglutide and tirzepatide are increasingly used for obesity treatment, with their growing popularity raising questions about side effects, long-term safety, and risks from unregulated products. The study highlights the need for oversight, monitoring, and coordinated clinical care to ensure safe access to these medications.
AI summary of the abstract below.
| Journal | PLoS Med, 2026 |
|---|---|
| Citations | 1 |
| Molecules | — |
| Conditions studied | Obesity |
Abstract
Glucagon-like peptide-1 (GLP-1)-based medications, such as semaglutide and tirzepatide, have transformed obesity care. However, rising use brings concerns about side effects, long-term outcomes, and unregulated products. Ensuring safe access requires oversight, monitoring, and coordinated clinical care.
Verbatim abstract via PubMed 41533690 ↗